Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, discusses Juvena’s "pipeline in a product" JUV-161 and plans to broaden into other disease indications.

Avidity Biosciences receives Japan MHLW’s orphan drug status for delpacibart etedesiran to treat myotonic dystrophy type 1: San Diego Thursday, April 10, 2025, 13:00 Hrs [IST] A ...

Avidity Biosciences, Inc.’s RNA share price has dipped by 7.10%, which has investors questioning if this is right time to buy ...

Avidity Biosciences, Inc. , a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCstm), today announced that the Japan ...

Mexiletine appears to be safe and is likely an effective treatment for managing symptoms of myotonia (delayed muscle relaxation after a contraction) in people wit ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2025 financial results on Monday, May 5, ...